SCHEMBL15638643

SCHEMBL15638643

Nc1ccc(Br)cc1Nc1ccc(F)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
SOS1 Q07889 1/20 0.42
MAP2K1 Q02750 2/20 0.39
MAP2K2 P36507 1/20 0.39
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
HDAC1 Q13547 2/20 0.37
LMNA P02545 2/20 0.36
THRB P10828 1/20 0.36
MAPT P10636 2/20 0.35
TP53 P04637 2/20 0.35
IDO1 P14902 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15639471 0.84 KMT2A (0.41) ALDH1A1MAP2K1MAP2K2NPC1RAB9A
SCHEMBL15638942 0.79 HDAC1 (0.42) ALDH1A1SOS1CYP2D6CYP2C19NPC1
SCHEMBL29581577 0.77 ALDH1A1 (0.47) ALDH1A1SOS1CYP2D6CYP2C19NPC1
SCHEMBL3606443 0.77 ALDH1A1 (0.47) ALDH1A1SOS1CYP2D6CYP2C19NPC1
SCHEMBL9535914 0.76 MAP2K1 (0.47) ALDH1A1SOS1MAP2K1CYP2D6CYP2C19
SCHEMBL9535897 0.75 HDAC1 (0.50) ALDH1A1SOS1CYP2C19NPC1RAB9A
SCHEMBL20155425 0.75 SOS1 (0.46) ALDH1A1SOS1CYP2D6CYP2C19NPC1
SCHEMBL9538256 0.74 HDAC1 (0.49) ALDH1A1CYP2C19NPC1RAB9ASMN1; SMN2
SCHEMBL11901667 0.74 CCNC (0.50) ALDH1A1CYP2D6CYP2C19NPC1RAB9A
SCHEMBL20155496 0.73 SOS1 (0.42) ALDH1A1SOS1CYP2D6CYP2C19NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903980-B1 BENZIMIDAZOLES AS CNS ACTIVE AGENTS HOFFMANN LA ROCHE (CH) 2017-07-19 EP disclosed
US-9365550-B2 Benzimidazoles as CNS active agents HOFFMANN-LA ROCHE INC. (US) 2016-06-14 US disclosed
EP-2903980-A1 BENZIMIDAZOLES AS CNS ACTIVE AGENTS F. Hoffmann-La Roche AG (CH) 2015-08-12 EP disclosed
US-20150203472-A1 BENZIMIDAZOLES AS CNS ACTIVE AGENTS HOFFMANN-LA ROCHE INC. (US) 2015-07-23 US disclosed
WO-2014053409-A1 BENZIMIDAZOL.ES AS CNS ACTIVE AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2014-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203472-A1 BENZIMIDAZOLES AS CNS ACTIVE AGENTS CDR2, HTR2B, HCRTR1 ALDH1A1 539/4885SOS1 2133/4885MAP2K1 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.